[HTML][HTML] A phase 1 study investigating DX-2930 in healthy subjects
Y Chyung, B Vince, R Iarrobino, D Sexton… - Annals of Allergy …, 2014 - Elsevier
Background DX-2930 is a human monoclonal antibody inhibitor of plasma kallikrein under
investigation for long-term prophylaxis of hereditary angioedema. Objective To assess the
safety, tolerability, pharmacokinetics, and pharmacodynamics of DX-2930 in healthy
subjects. Methods A single-center, double-blinded study was performed in 32 healthy
subjects randomized 3: 1 to receive a single subcutaneous administration of DX-2930 or
placebo within 1 of 4 sequential, ascending dose cohorts (n= 8 each): 0.1, 0.3, 1.0, or 3.0 …
investigation for long-term prophylaxis of hereditary angioedema. Objective To assess the
safety, tolerability, pharmacokinetics, and pharmacodynamics of DX-2930 in healthy
subjects. Methods A single-center, double-blinded study was performed in 32 healthy
subjects randomized 3: 1 to receive a single subcutaneous administration of DX-2930 or
placebo within 1 of 4 sequential, ascending dose cohorts (n= 8 each): 0.1, 0.3, 1.0, or 3.0 …